112 related articles for article (PubMed ID: 1425830)
1. Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer--an update.
Javadpour N; Guirguis R
Eur Urol; 1992; 21 Suppl 1():1-4. PubMed ID: 1425830
[TBL] [Abstract][Full Text] [Related]
2. Tumor collagenase stimulating factor (TCSF) and tumor autocrine motility factor (TAMF) in bladder cancer.
Javadpour N; Guirguis R
Prog Clin Biol Res; 1991; 370():393-8. PubMed ID: 1924475
[No Abstract] [Full Text] [Related]
3. A new method for evaluation of urinary autocrine motility factor and tumor cell collagenase stimulating factor as markers for urinary tract cancers.
Guirguis R; Javadpour N; Sharareh S; Biswas C; el-Amin W; Mansur I; Kim JS
J Occup Med; 1990 Sep; 32(9):846-53. PubMed ID: 2127427
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers.
Muraoka K; Nabeshima K; Murayama T; Biswas C; Koono M
Int J Cancer; 1993 Aug; 55(1):19-26. PubMed ID: 8344748
[TBL] [Abstract][Full Text] [Related]
5. Detection of autocrine motility factor in urine as a marker of bladder cancer.
Guirguis R; Schiffmann E; Liu B; Birkbeck D; Engel J; Liotta L
J Natl Cancer Inst; 1988 Oct; 80(15):1203-11. PubMed ID: 3138430
[TBL] [Abstract][Full Text] [Related]
6. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
7. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
8. Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers.
Polette M; Gilles C; Marchand V; Lorenzato M; Toole B; Tournier JM; Zucker S; Birembaut P
J Histochem Cytochem; 1997 May; 45(5):703-9. PubMed ID: 9154157
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
Buchumensky V; Klein A; Zemer R; Kessler OJ; Zimlichman S; Nissenkorn I
J Urol; 1998 Dec; 160(6 Pt 1):1971-4. PubMed ID: 9817302
[TBL] [Abstract][Full Text] [Related]
11. Urinary carcinoembryonic-like antigen levels in patients with bladder carcinoma.
Guinan P; John T; Sadoughi N; Ablin RJ; Bush I
J Urol; 1974 Mar; 111(3):350-2. PubMed ID: 4813575
[No Abstract] [Full Text] [Related]
12. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
14. Markers of bladder cancer.
Mostofi FK
J Natl Cancer Inst; 1988 Oct; 80(15):1184. PubMed ID: 3138429
[No Abstract] [Full Text] [Related]
15. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
16. Urine cytology, tumour markers and bladder cancer.
Halachmi S; Linn JF; Amiel GE; Moskovitz B; Nativ O
Br J Urol; 1998 Nov; 82(5):647-54. PubMed ID: 9839578
[No Abstract] [Full Text] [Related]
17. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
18. Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder.
Fradet Y; Lafleur L; LaRue H
J Cell Biochem Suppl; 1992; 16I():85-92. PubMed ID: 1305695
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
20. Cell and tumor markers' immunohistochemistry in transitional cell carcinoma of the bladder.
Lopez-Beltran A; Croghan GA; Croghan I; Gaeta JF
Urol Int; 1993; 50(2):61-4. PubMed ID: 8460449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
